Literature DB >> 8606122

Oral immunization with a recombinant cysteine-rich section of the Entamoeba histolytica galactose-inhibitable lectin elicits an intestinal secretory immunoglobulin A response that has in vitro adherence inhibition activity.

D E Beving1, C J Soong, J I Ravdin.   

Abstract

The LC3-encoded 52-kDa recombinant protein includes amino acids 758 to 1134 of the 170-kDa subunit of the galactose-inhibitable lectin. Oral immunization of BALB/c mice with the LC3-encoded protein and cholera holotoxin induced an intestinal secretory immunoglobulin A (IgA) response (P < 0.01 compared with the control). There was a negative correlation (P = 0.001) between intestinal anti-LC3 IgA and serum IgA and IgG antibody responses. Intestinal secretions from immunized mice completely inhibited the galactose-specific adherence of axenic trophozoites ot Chinese hamster ovary cells (P < 0.01).

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8606122      PMCID： PMC173947          DOI： 10.1128/iai.64.4.1473-1476.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  24 in total

1.  Diagnosis of intestinal amebiasis using salivary IgA antibody detection.

Authors:  R del Muro; E Acosta; E Merino; W Glender; L Ortiz-Ortiz
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

Review 2.  Mucosal immunity: implications for vaccine development.

Authors:  J Holmgren; C Czerkinsky; N Lycke; A M Svennerholm
Journal:  Immunobiology       Date:  1992-02       Impact factor: 3.144

3.  Salivary IgA antibody detection in invasive amebiasis and in asymptomatic infection.

Authors:  A Aceti; A Pennica; D Celestino; M Caferro; O Leri; N Catalini; A Sebastiani
Journal:  J Infect Dis       Date:  1991-09       Impact factor: 5.226

4.  The prevalence of Entamoeba histolytica in lactating women and in their infants in Bangladesh.

Authors:  A Islam; B J Stoll; I Ljungstrom; J Biswas; H Nazrul; G Huldt
Journal:  Trans R Soc Trop Med Hyg       Date:  1988       Impact factor: 2.184

5.  Binding and internalization of rat colonic mucins by the galactose/N-acetyl-D-galactosamine adherence lectin of Entamoeba histolytica.

Authors:  K Chadee; M L Johnson; E Orozco; W A Petri; J I Ravdin
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

6.  Adoptive transfer of gut mucosal antitoxin memory by isolated B cells 1 year after oral immunization with cholera toxin.

Authors:  N Lycke; J Holmgren
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

7.  Five-year immunologic memory in Swedish volunteers after oral cholera vaccination.

Authors:  M Jertborn; A M Svennerholm; J Holmgren
Journal:  J Infect Dis       Date:  1988-02       Impact factor: 5.226

8.  Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens.

Authors:  N Lycke; J Holmgren
Journal:  Immunology       Date:  1986-10       Impact factor: 7.397

9.  Rat and human colonic mucins bind to and inhibit adherence lectin of Entamoeba histolytica.

Authors:  K Chadee; W A Petri; D J Innes; J I Ravdin
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

10.  Antibodies against Entamoeba histolytica in human milk and serum in Kenya.

Authors:  M S Grundy; L Cartwright-Taylor; L Lundin; C Thors; G Huldt
Journal:  J Clin Microbiol       Date:  1983-05       Impact factor: 5.948
View more
  10 in total

Review 1.  The immunobiology of Acanthamoeba keratitis.

Authors:  J Y Niederkorn; H Alizadeh; H F Leher; J P McCulley
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Progress towards development of a vaccine for amebiasis.

Authors:  S L Stanley
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

Review 3.  The immunology of parasite infections in immunocompromised hosts.

Authors:  T Evering; L M Weiss
Journal:  Parasite Immunol       Date:  2006-11       Impact factor: 2.280

4.  Expression, purification, and evaluation of recombinant LecA as a candidate for an amebic colitis vaccine.

Authors:  L Barroso; M Abhyankar; Z Noor; K Read; K Pedersen; R White; C Fox; W A Petri; D Lyerly
Journal:  Vaccine       Date:  2013-07-01       Impact factor: 3.641

5.  Mucosal immunogenicity of a holotoxin-like molecule containing the serine-rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin.

Authors:  F Sultan; L L Jin; M G Jobling; R K Holmes; S L Stanley
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

Review 6.  Host-pathogen interaction in amebiasis and progress in vaccine development.

Authors:  C D Huston; W A Petri
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

7.  Intestinal antilectin immunoglobulin A antibody response and immunity to Entamoeba dispar infection following cure of amebic liver abscess.

Authors:  Jonathan I Ravdin; Mohamed D Abd-Alla; Seth L Welles; Selvan Reddy; Terry F H G Jackson
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

8.  Adherence-inhibitory intestinal immunoglobulin a antibody response in baboons elicited by use of a synthetic intranasal lectin-based amebiasis subunit vaccine.

Authors:  Mohamed D Abd Alla; Gary L White; Tyson B Rogers; Max E Cary; David W Carey; Jonathan I Ravdin
Journal:  Infect Immun       Date:  2007-05-25       Impact factor: 3.441

9.  Identification of the Entamoeba histolytica galactose-inhibitable lectin epitopes recognized by human immunoglobulin A antibodies following cure of amebic liver abscess.

Authors:  Mohamed D Abd-Alla; Terry F G H Jackson; Ginny C Soong; Mary Mazanec; Jonathan I Ravdin
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

10.  Mucosal delivery of ACNPV baculovirus driving expression of the Gal-lectin LC3 fragment confers protection against amoebic liver abscess in hamster.

Authors:  D M Meneses-Ruiz; J P Laclette; H Aguilar-Díaz; J Hernández-Ruiz; A Luz-Madrigal; A Sampieri; L Vaca; J C Carrero
Journal:  Int J Biol Sci       Date:  2011-11-01       Impact factor: 6.580
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.